{"id":3781,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2010-03-29","marketCap":3.314176082611084,"name":"Tonix Pharmaceuticals Holding Corp","phone":"12129809155","outstanding":95.54000091552734,"symbol":"TNXP","website":"https://www.tonixpharma.com/","industry":"Biotechnology"},"price":1.1325,"year":2024,"month":6,"day":13,"weekday":"Thursday","title":"Competitive advantages and challenges of Tonix Pharmaceuticals in international markets","date":"2024-06-13","url":"/posts/2024/06/13/TNXP","content":[{"section":"Competitive advantages","text":"1. Innovative product portfolio: Tonix Pharmaceuticals has a strong pipeline of innovative drugs that target various therapeutic areas, giving them a competitive edge in the global pharmaceutical market.\n\n2. Strong research and development capabilities: The company's focus on research and development allows them to bring new and effective drugs to the market, attracting international customers seeking advanced pharmaceutical solutions.\n\n3. Intellectual property rights: Tonix Pharmaceuticals holds numerous patents for their drugs, providing them with protection against competitors and creating barriers to entry for potential rivals."},{"section":"Challenges","text":"1. Regulatory hurdles: Tonix Pharmaceuticals must navigate complex and varying regulations in different international markets, which can slow down the approval process and create market entry barriers.\n\n2. Pricing pressures: The global pharmaceutical market is highly competitive, and Tonix Pharmaceuticals may face challenges in pricing their products competitively while maintaining profitability.\n\n3. Cultural and language barriers: Entering international markets requires understanding and adapting to different cultures and languages, which can present communication and marketing challenges for the company."},{"section":"Global expansion strategies","text":"1. Partnering with local distributors or pharmaceutical companies: Tonix Pharmaceuticals can leverage the expertise and existing distribution networks of local partners to gain access to international markets more effectively.\n\n2. Conducting market research: Thorough market research will help Tonix Pharmaceuticals understand the needs and preferences of the target markets, enabling them to develop tailored marketing and product strategies.\n\n3. Establishing strategic alliances: Collaborating with international pharmaceutical companies or research institutions can provide Tonix Pharmaceuticals with valuable resources, knowledge sharing, and market access opportunities."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1718140620,"headline":"Tonix Pharmaceuticals Announces Proposed Public Offering","id":128215220,"image":"https://media.zenfs.com/en/globenewswire.com/2260880378e4d1a1a54ac9ee6eda14bf","symbol":"TNXP","publisher":"Yahoo","summary":"CHATHAM, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof). All of the securities to be sold in the offering are to be offered by Tonix. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, o","url":"https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-proposed-public-211700025.html"},{"category":"company","date":1718018220,"headline":"SOUN Stock Alert: SoundHound AI Pays Off Debt Early","id":128180631,"image":"","symbol":"TNXP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3534478219"},{"category":"company","date":1718017140,"headline":"Why Is Tonix Pharmaceuticals (TNXP) Stock Down 31% Today?","id":128185746,"image":"","symbol":"TNXP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3534455764"},{"category":"company","date":1718011080,"headline":"Tonix Pharma Updates Investors and Engages with FDA","id":128179412,"image":"","symbol":"TNXP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3534344855"},{"category":"company","date":1718011020,"headline":"US Stocks Mixed; Perion Network Shares Plunge","id":128179413,"image":"","symbol":"TNXP","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3534344001"},{"category":"company","date":1717982100,"headline":"Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session","id":128182330,"image":"","symbol":"TNXP","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3534622107"},{"category":"company","date":1717743000,"headline":"Tonix Pharmaceuticals trading halted, news pending","id":128165182,"image":"","symbol":"TNXP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3531688356"},{"category":"company","date":1717686000,"headline":"Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split","id":128125033,"image":"https://media.zenfs.com/en/globenewswire.com/2260880378e4d1a1a54ac9ee6eda14bf","symbol":"TNXP","publisher":"Yahoo","summary":"CHATHAM, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock. The reverse stock split will be effective for trading purposes as of the commencement of trading on June 10, 2024. The reverse stock split is intended to increase the p","url":"https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-1-32-150000117.html"},{"category":"company","date":1717675200,"headline":"Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024","id":128125034,"image":"https://media.zenfs.com/en/globenewswire.com/2260880378e4d1a1a54ac9ee6eda14bf","symbol":"TNXP","publisher":"Yahoo","summary":"TNX-1500 displays potential as a monotherapy or combination therapy to prevent rejection in organ transplantation in allograft and xenograft animal models Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital Transplantation is also believed to be a model for treating autoimmunity CHATHAM, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company","url":"https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-two-oral-120000500.html"},{"category":"company","date":1717660800,"headline":"Tonix Pharma Advances in Transplant Medicine Research","id":128123459,"image":"","symbol":"TNXP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3529144014"},{"category":"company","date":1717657920,"headline":"Tonix Pharmaceuticals announces oral presentations involving TNX-1500","id":128123461,"image":"","symbol":"TNXP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3529087880"},{"category":"company","date":1717588800,"headline":"Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024","id":128108003,"image":"https://media.zenfs.com/en/globenewswire.com/2260880378e4d1a1a54ac9ee6eda14bf","symbol":"TNXP","publisher":"Yahoo","summary":"Presentation to highlight statistically significant Phase 3 results of Tonmya™ (TNX-102 SL) for the management of fibromyalgia New Drug Application (NDA) submission to the FDA on track for the second half of 2024 CHATHAM, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced a poster presentation at the Annual E","url":"https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-poster-presentation-120000555.html"},{"category":"company","date":1717416000,"headline":"Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting","id":128050128,"image":"https://media.zenfs.com/en/globenewswire.com/2260880378e4d1a1a54ac9ee6eda14bf","symbol":"TNXP","publisher":"Yahoo","summary":"Tonmya treatment was associated with improvement in depressive symptoms as measured by the Beck Depression Inventory-II In addition, post-hoc analyses showed improvement in depression, anxiety, memory and energy items on the Fibromyalgia Impact Questionnaire-Revised New Drug Application (NDA) submission to the FDA on track for the second half of 2024 CHATHAM, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biop","url":"https://finance.yahoo.com/news/tonix-pharmaceuticals-presented-data-tonmya-120000501.html"},{"category":"company","date":1717401240,"headline":"Tonix Pharma’s Tonmya™ Shows Broad-Spectrum Promise in Fibromyalgia","id":128052809,"image":"","symbol":"TNXP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3524036081"},{"category":"company","date":1717400280,"headline":"Tonix Pharmaceuticals presents new data on Tonmya at ASCP","id":128052810,"image":"","symbol":"TNXP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3524019207"},{"category":"company","date":1717070400,"headline":"Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting","id":127980843,"image":"https://media.zenfs.com/en/globenewswire.com/2260880378e4d1a1a54ac9ee6eda14bf","symbol":"TNXP","publisher":"Yahoo","summary":"In the Phase 2 PREVAIL trial in fibromyalgia-type Long COVID, bedtime TNX-102 SL resulted in a signal in fatigue, sleep and cognitive function Phase 2, investigator-initiated OASIS trial is designed to examine the safety and efficacy of TNX-102 SL in treating Acute Stress Disorder (ASD) after motor vehicle collision First patient in OASIS expected to enroll in second quarter 2024 CHATHAM, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Comp","url":"https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-two-poster-120000135.html"},{"category":"company","date":1717056720,"headline":"Tonix Pharma Advances with TNX-102 SL for Long COVID and Stress Disorders","id":127981817,"image":"","symbol":"TNXP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3518623617"},{"category":"company","date":1717053540,"headline":"Tonix Pharmaceuticals announces two poster presentations of TNX-102 SL","id":127981820,"image":"","symbol":"TNXP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3518559567"}]}